Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

医学 多药 糖尿病 低血糖 2型糖尿病 痴呆 药物治疗 二甲双胍 吡格列酮 糖尿病管理 重症监护医学 利拉鲁肽 内科学 内分泌学 疾病
作者
Miriam Longo,Giuseppe Bellastella,Maria Ida Maiorino,Juris J. Meier,Katherine Esposito,Dario Giugliano
出处
期刊:Frontiers in Endocrinology [Frontiers Media SA]
卷期号:10 被引量:145
标识
DOI:10.3389/fendo.2019.00045
摘要

Diabetes is becoming one of the most widespread health burning problems in the elderly. Worldwide prevalence of diabetes among subjects over 65 years was 123 million in 2017, a number that is expected to double in 2045. Old patients with diabetes have a higher risk of common geriatric syndromes, including frailty, cognitive impairment and dementia, urinary incontinence, traumatic falls and fractures, disability, side effects of polypharmacy, which have an important impact on quality of life and may interfere with anti-diabetic treatment. Because of all these factors, clinical management of type 2 diabetes in elderly patients currently represents a real challenge for the physician. Actually, the optimal glycemic target to achieve for elderly diabetic patients is still a matter of debate. The American Diabetes Association suggests a HbA1c goal 6.5%) for patients with concurrent serious illness and at high risk of hypoglycemia. By contrast, the American College of Physicians (ACP) suggests more conservative goals (HbA1c levels between 7% and 8%) for most older patients, and a less intense pharmacotherapy, when HbA1C levels are ≤ 6.5%. Management of glycemic goals and antihyperglycemic treatment has to be individualized in accordance to medical history and comorbidities, giving preference to drugs that are associated with low risk of hypoglycemia. Antihyperglycemic agents considered safe and effective for type 2 diabetic older patients include: metformin (the first-line agent), pioglitazone, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists. Insulin secretagogue agents have to be used with caution because of their significant hypoglycemic risk; if used, short-acting sulfonylureas, as gliclazide, or glinides as repaglinide, should be preferred. When using complex insulin regimen in old people with diabetes, attention should be paid for the risk of hypoglycemia. In this paper we aim to review and discuss the best glycemic targets as well as the best treatment choices for older people with type 2 diabetes based on current international guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
是风动发布了新的文献求助10
刚刚
aaaaaah完成签到,获得积分10
刚刚
以韓完成签到 ,获得积分10
1秒前
香蕉觅云应助迅速的念芹采纳,获得10
1秒前
阔达棉花糖完成签到,获得积分10
1秒前
1秒前
3秒前
xinggui发布了新的文献求助10
3秒前
开心夜云发布了新的文献求助10
4秒前
4秒前
ning发布了新的文献求助10
4秒前
king756796723完成签到,获得积分10
4秒前
哭泣忆文完成签到,获得积分10
5秒前
wxcx完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
简木完成签到,获得积分10
6秒前
科研通AI2S应助tianshuai采纳,获得10
7秒前
魁拔蛮吉发布了新的文献求助10
7秒前
二一而已发布了新的文献求助10
7秒前
刘尹完成签到,获得积分10
7秒前
8秒前
Raine完成签到,获得积分10
8秒前
8秒前
脆脆鲨发布了新的文献求助10
9秒前
9秒前
翻译度完成签到,获得积分10
10秒前
lili完成签到,获得积分10
10秒前
10秒前
wangjing完成签到,获得积分10
10秒前
冰冰娃发布了新的文献求助10
10秒前
花佩剑完成签到,获得积分10
11秒前
落叶发布了新的文献求助10
11秒前
11秒前
zizou633完成签到,获得积分20
12秒前
汉堡包应助佩楠采纳,获得10
12秒前
ZHAO完成签到,获得积分10
12秒前
77发布了新的文献求助10
12秒前
AXNUV发布了新的文献求助10
13秒前
高分求助中
Medicina di laboratorio. Logica e patologia clinica 600
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
Machine Learning for Polymer Informatics 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
2024 Medicinal Chemistry Reviews 480
Women in Power in Post-Communist Parliaments 450
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3217056
求助须知:如何正确求助?哪些是违规求助? 2866278
关于积分的说明 8151168
捐赠科研通 2532940
什么是DOI,文献DOI怎么找? 1365978
科研通“疑难数据库(出版商)”最低求助积分说明 644655
邀请新用户注册赠送积分活动 617611